Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec;18(12):2693-2694.
doi: 10.4103/1673-5374.373710.

Cell replacement for Parkinson's disease: advances and challenges

Bin Xiao  1 , Eng-King Tan  2
Affiliations

Cell replacement for Parkinson's disease: advances and challenges

Bin Xiao et al. Neural Regen Res. 2023 Dec.
No abstract available

PubMed Disclaimer

Conflict of interest statement

None

Figures

Figure 1
Figure 1
Sources of cell therapy for PD. The field of cell therapy for PD has been constantly evolving. Historically, it started with transplantation of the adrenal medulla which has been abandoned in clinical practice. Transplantation of fetal ventral mesencephalic neurons has yielded mixed clinical outcomes with some patients enjoying long-term disease-free life. It provides proof-of-concept evidence for cell therapy as a viable option for PD but will less likely become a therapeutic norm for the general PD population. Currently, cell therapy utilizing human induced pluripotent stem cells (iPSCs)-derived graft overcomes the major hurdles that embryonic stem cells (ESCs)-based therapy encounters and holds great potential as a routine therapeutic option for PD. In the future, the direct conversion and transplantation of midbrain organoids for PD therapy are promising areas of research. PD: Parkinson’s disease. Created with BioRender.com.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Barker RA, Barrett J, Mason SL, Bjorklund A. Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease. Lancet Neurol. 2013;12:84–91. - PubMed
    1. Barker RA. TRANSEURO consortium (2019) Designing stem-cell-based dopamine cell replacement trials for Parkinson's disease. Nat Med. 25:1045–1053. - PubMed
    1. Bohn MC, Cupit L, Marciano F, Gash DM. Adrenal medulla grafts enhance recovery of striatal dopaminergic fibers. Science. 1987;237:913–916. - PubMed
    1. Chen Y, Xiong M, Dong Y, Haberman A, Cao J, Liu H, Zhou W, Zhang SC. Chemical control of grafted human PSC-derived neurons in a mouse model of Parkinson's disease. Cell Stem Cell. 2016;18:817–826. - PMC - PubMed
    1. Jo J, Yang L, Tran HD, Yu W, Sun AX, Chang YY, Jung BC, Lee SJ, Saw TY, Xiao B, Khoo ATT, Yaw LP, Xie JJ, Lokman H, Ong WY, Lim GGY, Lim KL, Tan EK, Ng HH, Je HS. Lewy body-like inclusions in human midbrain organoids carrying glucocerebrosidase and alpha-synuclein mutations. Ann Neurol. 2021;90:490–505. - PMC - PubMed